Navigation Links
Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
Date:8/3/2009

MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths. Metoprolol succinate extended-release tablets are the generic equivalent to AstraZeneca's Toprol XL(R) tablets. Metoprolol succinate extended-release is a beta-blocker used to treat angina, heart failure and high blood pressure. Watson intends to launch the product immediately.

Toprol XL(R) 25 mg and 50 mg and its generic equivalents had annual sales of approximately $628 million for the twelve months ending June 2009, according to IMS sales data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

Toprol XL(R) is a registered trademark of AstraZeneca PLC.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... Valley, CA (PRWEB) , ... June 23, 2017 , ... ... Blue Belle, were recently denied entry to the JFK Virgin Atlantic lounge. , ... her into a wheelchair six years ago, Bensko dedicated her life to supporting our ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... Kan. (PRWEB) , ... June 23, 2017 , ... Goodcents ... , The restaurant is located at 4210 SW 21st St. Topeka, Kan. 66604 ... Graham, owner of Graham Restaurant Group who owns three other locations in the Topeka ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has ... Dr. Talei has come up with a proprietary technique that he calls the ... that have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring ... two new videos highlight the importance of correctly using a meat thermometer. The ... has done extensive research on consumer food safety habits. Dr. Bruhn explains the ...
Breaking Medicine News(10 mins):
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 /PRNewswire/ ... validate the use of MMprofiler with SKY92, the company,s ... (MM). In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will ... elderly patients. In a separate e-poster ...
(Date:6/20/2017)... , June 19, 2017  Hill-Rom Holdings, Inc. (NYSE: ... call and webcast on Friday, July 28, 2017, beginning at ... Call Audio Only Dial-in information: To participate in the conference ... dial into the call at least 10 minutes prior to ... is 34090339.  Webcast: ...
(Date:6/19/2017)... June 19, 2017  Researchers from DRUGSCAN ® ... will host a live, complimentary webinar titled, "Untangling methods ... to the real world" on Wednesday June 28, 2017 ... This webinar will feature interviews with recreational and ... the manipulation techniques abusers use to prepare opioid tablets ...
Breaking Medicine Technology: